---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000137"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:41:15.126679+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition

## Summary
- Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.
- Reiterates FY2024 product revenue guidance $10.55-$10.75B; combined non-GAAP R&D and SG&A $4.3-$4.4B.
- Submitted NDA (priority review) for vanzacaftor triple in CF to FDA and MAA to EMA; rolling NDA for suzetrigine in acute pain.
- Entered agreement to acquire Alpine Immune Sciences for ~$4.9B ($65/sh cash); expected close Q2 2024.
- Cash and marketable securities $14.6B; >25 CASGEVY ATCs activated globally; multiple patients started cell collection.

## SEC filing metadata
- accession: 0000875320-24-000137
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/vrtx-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000137
- JSON: https://secwatch.observer/filing/0000875320-24-000137.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000137.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported full year 2024 results: revenue 10.55 to 10.75 billion. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: 10.55 to 10.75 billion
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported first quarter ended March 31, 2024 results: revenue 2.69 billion.
  - Period: first quarter ended March 31, 2024
  - Revenue: 2.69 billion
  - Result: reported results
  source text: as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% i ncrease compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.